Nevro Receives Expanded FDA Approval for Spinal Cord Stimulation System

January 25, 2022

Redwood City, Calif.-based Nevro has received the FDA’s expanded labeling approval for its Senza spinal cord stimulation system.

The newly approved indication for the company’s proprietary 10 kHz stimulation therapy is for the treatment of nonsurgical refractory back pain (NSRBP). The system was previously approved for patients with diabetic neuropathy.

Sensa is the only product with specific, on-label indications for treating both NSRBP and painful diabetic neuropathy, the company said.

View today's stories